Irland - engelsk - HPRA (Health Products Regulatory Authority)

hospira uk ltd - cefuroxime sodium - powder for suspension for injection - 250 milligram

Malta - engelsk - Medicines Authority

villerton invest s.a. rue edward steichen 14, 2540, luxembourg - cefuroxime - powder for solution for injection powder for suspension for injection - cefuroxime 250 mg - antibacterials for systemic use

Armenia - engelsk - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

olainfarm jsc - ethacizine - tablets coated - 50mg

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: sodium sulfate; sulfuric acid; sodium acetate trihydrate; water for injections - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - moxifloxacin hydrochloride, quantity: 1.75 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; sodium acetate trihydrate; sodium sulfate; sulfuric acid - moxifloxacin kabi intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions:,- community acquired pneumonia (caused by susceptible organisms),- acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics,- moxifloxacin kabi intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents, (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin.,appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin kabi may be initiated, in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - linezolid, quantity: 2 mg/ml - injection, solution - excipient ingredients: water for injections; glucose monohydrate; citric acid; hydrochloric acid; sodium citrate dihydrate; sodium hydroxide - zyvox is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. zyvox (linezolid) is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - linezolid, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium citrate dihydrate; water for injections; glucose monohydrate; sodium hydroxide; citric acid - zyvox is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. zyvox (linezolid) is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected..

Israel - engelsk - Ministry of Health

novartis israel ltd., israel - cefuroxime as sodium - powder for solution or suspension for injection or infusion - cefuroxime as sodium 750 mg/vial - cefuroxime - cefuroxime - therapeutic indications zinacef is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth)• community acquired pneumonia• acute exacerbations of chronic bronchitis• complicated urinary tract infections, including pyelonephritis• soft-tissue infections: cellulitis, erysipelas and wound infections• intra-abdominal infections • prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section) • nose infections for example, sinusitis • septic arthritis

Armenia - engelsk - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

olainfarm jsc - ethacizine - tablets coated - 50mg

New Zealand - engelsk - Ministry for Primary Industries

ethical agents veterinary marketing limited - penicillin g procaine - penicillin g procaine 300 g/litre - antibiotic